GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (FRA:I9DN) » Definitions » Cyclically Adjusted Price-to-FCF

Arbutus Biopharma (FRA:I9DN) Cyclically Adjusted Price-to-FCF : (As of Jun. 02, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Arbutus Biopharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arbutus Biopharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Arbutus Biopharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Cyclically Adjusted Price-to-FCF Chart

Arbutus Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arbutus Biopharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arbutus Biopharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted Price-to-FCF falls into.


;
;

Arbutus Biopharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Arbutus Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Arbutus Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.065/134.9266*134.9266
=-0.065

Current CPI (Mar. 2025) = 134.9266.

Arbutus Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.280 100.684 -0.375
201509 -0.055 100.392 -0.074
201512 -0.348 99.792 -0.471
201603 -0.207 100.470 -0.278
201606 -0.300 101.688 -0.398
201609 -0.247 101.861 -0.327
201612 -0.303 101.863 -0.401
201703 -0.361 102.862 -0.474
201706 -0.134 103.349 -0.175
201709 -0.248 104.136 -0.321
201712 -0.162 104.011 -0.210
201803 -0.298 105.290 -0.382
201806 -0.273 106.317 -0.346
201809 -0.208 106.507 -0.264
201812 -0.274 105.998 -0.349
201903 -0.264 107.251 -0.332
201906 -0.278 108.070 -0.347
201909 -0.379 108.329 -0.472
201912 -0.205 108.420 -0.255
202003 -0.207 108.902 -0.256
202006 -0.112 108.767 -0.139
202009 -0.130 109.815 -0.160
202012 -0.143 109.897 -0.176
202103 -0.162 111.754 -0.196
202106 -0.125 114.631 -0.147
202109 -0.135 115.734 -0.157
202112 -0.130 117.630 -0.149
202203 0.126 121.301 0.140
202206 -0.130 125.017 -0.140
202209 -0.126 125.227 -0.136
202212 -0.104 125.222 -0.112
202303 -0.158 127.348 -0.167
202306 -0.113 128.729 -0.118
202309 -0.122 129.860 -0.127
202312 -0.094 129.419 -0.098
202403 -0.102 131.776 -0.104
202406 -0.072 132.554 -0.073
202409 -0.099 133.029 -0.100
202412 -0.052 133.157 -0.053
202503 -0.065 134.927 -0.065

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arbutus Biopharma  (FRA:I9DN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Arbutus Biopharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma Business Description

Industry
Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Arbutus Biopharma Headlines

No Headlines